In recent years, cancer immunotherapy has made remarkable progress, revolutionizing cancer treatment. Our Special Issue "Cancer Immunology" in the journal Cancers showcased cutting-edge research and reviews. Building on that success, this new Special Issue explores recent advancements, technologies, and future prospects in cancer immunology, pre-clinical assessments, and clinical trials. While immune checkpoint inhibitors have been transformative, addressing limited response remains crucial. Strategies to overcome ...
Read More
In recent years, cancer immunotherapy has made remarkable progress, revolutionizing cancer treatment. Our Special Issue "Cancer Immunology" in the journal Cancers showcased cutting-edge research and reviews. Building on that success, this new Special Issue explores recent advancements, technologies, and future prospects in cancer immunology, pre-clinical assessments, and clinical trials. While immune checkpoint inhibitors have been transformative, addressing limited response remains crucial. Strategies to overcome resistance, such as combination therapies and targeted pathways, are discussed in the issue. Chimeric antigen receptor (CAR) T cell therapy is an important area of immunotherapy, with exciting findings for enhancing CAR persistence and efficacy. Conventional treatments and monoclonal antibodies also activate immunological mechanisms, boosting cytotoxic efficacy against specific cancers. Identifying biomarkers associated with treatment response is vital for personalized cancer immunotherapy. Potential biomarkers like immune cell densities and estrogen receptor expression are explored in this Issue. The review articles cover advancements in CAR T cell therapy, tumor metabolic alterations, immune suppressive cells, and the role of bacteria in cancer immunotherapy. This Special Issue is a valuable resource for researchers, clinicians, and industry professionals, guiding future developments towards more effective and personalized cancer immunotherapies.
Read Less
Add this copy of Tumor Immunology and Immunotherapy Resistance to cart. $67.56, new condition, Sold by Books2anywhere rated 5.0 out of 5 stars, ships from Fairford, GLOUCESTERSHIRE, UNITED KINGDOM, published 2023 by MDPI AG.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
PLEASE NOTE, WE DO NOT SHIP TO DENMARK. New Book. Shipped from UK in 4 to 14 days. Established seller since 2000. Please note we cannot offer an expedited shipping service from the UK.
Add this copy of Tumor Immunology and Immunotherapy Resistance to cart. $65.97, new condition, Sold by Ria Christie Books rated 4.0 out of 5 stars, ships from Uxbridge, MIDDLESEX, UNITED KINGDOM, published 2023 by Mdpi AG.
Add this copy of Tumor Immunology and Immunotherapy Resistance to cart. $78.45, new condition, Sold by Booksplease rated 3.0 out of 5 stars, ships from Southport, MERSEYSIDE, UNITED KINGDOM, published 2023 by Mdpi AG.
Add this copy of Tumor Immunology and Immunotherapy Resistance to cart. $73.42, new condition, Sold by Paperbackshop International rated 2.0 out of 5 stars, ships from Fairford, GLOS, UNITED KINGDOM, published 2023 by MDPI AG.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
PLEASE NOTE, WE DO NOT SHIP TO DENMARK. New Book. Shipped from UK in 4 to 14 days. Established seller since 2000. Please note we cannot offer an expedited shipping service from the UK.
Add this copy of Tumor Immunology and Immunotherapy Resistance to cart. $62.99, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 2023 by Mdpi AG.
Add this copy of Tumor Immunology and Immunotherapy Resistance to cart. $84.85, good condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Newport Coast, CA, UNITED STATES, published 2023 by Mdpi AG.
Add this copy of Tumor Immunology and Immunotherapy Resistance to cart. $116.11, new condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Newport Coast, CA, UNITED STATES, published 2023 by Mdpi AG.
